Oral abstract presentation times
11th Rapid Fire
11th Oral
12th Rapid Fire
Abstract ID: 26-579
Tear Film and Ocular Surface Outcomes After Adjunctive Periorbital Polyrevitalization Mesotherapy in Dry Eye Disease: A Randomized, Assessor-Masked Pilot Study
Author: Bora Deniz Argon Base Hospital / Institution: University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital
Presentation Type: Rapid Fire Presentation Session: Trauma / War / MiscellaneousDate: 12th SeptemberTime: 16.53
Purpose
To evaluate ocular surface safety and exploratory efficacy of adjunctive periorbital NCTF® 135 HA mesotherapy in dry eye disease (DED).
Methods
Prospective, randomized, controlled, assessor-masked pilot study. Forty patients with mixed-mechanism DED on stable topical sodium hyaluronate 0.2% plus carbomer 980 gel for ≥3 months were randomized 1:1 to topical therapy alone (control, n=20) or topical therapy plus three periorbital mesotherapy sessions on Days 0, 15 and 30 (n=20). Allocation used block randomization and sealed envelopes. Patient masking was not feasible. Primary endpoint was OSDI change at Day 90. Secondary endpoints included TBUT, NIBUT, Schirmer I, corneal and conjunctival staining, TMH, osmolarity, MGD parameters, and safety.
Results
Baseline parameters were comparable. At Day 90, OSDI improved more with mesotherapy than control (–8.7±6.6 vs –3.9±5.1; p=0.014). TBUT improvement was also greater (+0.7±0.7 vs +0.2±0.5 s; p=0.012). NIBUT showed a non-significant same-direction trend (+0.5±0.7 vs +0.3±0.5 s; p=0.233). Schirmer I, conjunctival staining, hyperemia, TMH, osmolarity, meibum quality and incomplete blink percentage did not differ significantly. Corneal staining showed a small greater improvement (–0.45±0.51 vs –0.15±0.37; p=0.043). Transient local edema, ecchymosis, injection-site pain and mild hyperemia worsening resolved spontaneously; no allergic reaction, epithelial defect, infection/cellulitis or serious adverse event occurred.
Conclusion
Adjunctive periorbital NCTF® 135 HA mesotherapy was well tolerated and associated with greater symptom and fluorescein TBUT improvement at 90 days, without clear superiority in most other objective ocular surface or MGD-related parameters. Larger sham-controlled trials are warranted.
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Emetullah Feyza | Altın | University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital |
| Kardelen | Uzun | University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital |